目的 探讨蛋白酶体抑制剂胶毒素与内质网应激诱导剂衣霉素联合对肿瘤细胞的凋亡诱导能力。方法 采用四甲基偶氮唑蓝法观察药物对肿瘤细胞增殖的抑制作用;采用两药相互作用指数评价药物联合是否存在协同作用。采用流式细胞术结合annexin V/PI双染法检测细胞凋亡比例。采用蛋白质印迹法检测相关蛋白的表达水平。结果 胶毒素与衣霉素对人纤维肉瘤HT-1080细胞的IC50值分别为(1.44±0.23)和(26.14±6.14) μmol·L-1。在有效剂量下,胶毒素与衣霉素联合可以使细胞出现典型的凋亡和坏死的形态改变,两药联合可以产生协同作用。流式细胞术检测结果显示,胶毒素与衣霉素联合后,细胞凋亡比例显著上升。尤其是0.2 μmol·L-1胶毒素联合衣霉素组,凋亡比例达到66.6%,两药相互作用指数为0.649。蛋白质印迹法检测结果显示,凋亡相关蛋白caspase-8、caspase-3、PARP及NF-kB表达水平发生相应改变。结论 胶毒素可以显著增强内质网应激诱导剂衣霉素对HT-1080的凋亡诱导能力,这一研究结果为抗肿瘤药物的联合提供了新的给药方案。
Abstract
ObjectiveTo investigate whether the proteasome inhibitor, gliotoxin, combined with the endoplasmic reticulum stress inducer, tunicamycin, could enhance the apoptotic death of tumor cells. Methods MTT assay was used to detect the cytotoxicity. The combined drug index (CDI) was used to evaluate the synergistic effect. Flow cytometry was used to analyze the apoptosis rate. The protein expression level was detected by Western blot. Results The IC50 of gliotoxin and tunicamycin is (1.44±0.23) and (26.14±6.14) μmol·L-1, respectively. In the effective concentration, gliotoxin combined with tunicamycin could significantly inhibit cell proliferation and induce typical apoptotic morphological changes. The combination was synergistic according to the result of MTT assay. As measured by flow cytometry, the combination remarkably increased the apoptosis rates of HT-1080 cells, especially for 0.2 μmol·L-1 gliotoxin combined with tunicamycin, the apoptosis rate was up to 66.6% and CDI was 0.649. The expression changes of apoptosis-related proteins such as caspase-8, caspase-3, PARP and NF-kB were detected when treated with the combination. Conclusion Gliotoxin can improve the chemosensitivity of fibrosarcoma HT-1080 cells to tunicamycin and enhance the apoptosis of tumor cells induced by tunicamycin. Thus, our study may provide a new drug combination to antitumor therapy.
关键词
内质网应激 /
蛋白酶体 /
胶毒素 /
衣霉素 /
凋亡 /
肿瘤
{{custom_keyword}} /
Key words
endoplasmic reticulum stress /
proteasome /
gliotoxin /
tunicamycin /
apoptosis /
tumor
{{custom_keyword}} /
中图分类号：
R965
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] KROLL M, ARENZANA-SEISDEDOS F, BACHELERIE F, et al. The secondary fungal metabolite gliotoxin targets proteolyticactivities of the proteasome . Chem Biol, 1999, 6(10): 689-698.
[2] CARLBERG M, DRICU A, BLEGEN, et al. Short exposures to tunicamycin induce apoptosis in SV40-transformed but not in normal human fibroblasts . Carcinogenesis, 1996, 17(12): 2589-2596.
[3] DRICU A, CARLBERG M, WANG M, et al. Inhibition of N-linked glycosylation using tunicamycin causes cell death in malignant cells: Role of down-regulation of the insulin-like growth factor 1 receptor in induction of apoptosis . Cancer Res, 1997, 57(3): 543-548.
[4] ZIMMERMANN G R, LEHAR J, KEITH C T. Multi-target therapeutics: When the whole is greater than the sum of the parts . Drug Discov Today, 2007, 12 (1-2): 34-42.
[5] JIA J, ZHU F, MA X, et al. Mechanisms of drug combinations: Interaction and network perspectives . Nat Rev Drug Discov, 2009, 8(2): 111-128.
[6] NAUMANN K, SCHMICH K, JAEGER C, et al. Noxa/Mcl-1 balance influences the effect of the proteasome inhibitor MG-132 in combination with anticancer agents in pancreatic cancer cell lines . Anticancer Drugs, 2012 .
[7] TAYLOR-HARDING B, AGADJANIAN H, NASSANIAN H, et al. Indole-3-carbinol synergistically sensitises ovarian cancer cells to bortezomib treatment . Br J Cancer, 2012, 106(2): 333-343.
[8] WRIGHT J J. Combination therapy of bortezomib with novel targeted agents: An emerging treatment strategy . Clin Cancer Res, 2010, 16(16): 4094-4104.
[9] CIECHANOVER A. Intracellular protein degradation: From a vague idea thru the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting . Cell Death and Differ, 2005, 12(9): 1178-1190.
KOEPP D M, HARPER J W, ELLEDGE S J. How the cyclin became a cyclin: Regulated proteolysis in the cell cycle . Cell, 1999, 97(4): 431-434.
FRIBLEY A, WANG C Y. Proteasome inhibitor induces apoptosis through induction of endoplasmic reticulum stress . Cancer Biol Ther, 2006, 5(7): 745-748.
NAWROCKI S T, CAREW J S, PINO M S, et al. Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis . Cancer Res, 2005, 65(24):11658-11666.
SCHRODER M, KAUFMAN R J. ER stress and the unfolded protein response . Mutat Res, 2005, 569(1-2): 29-63.
SUN S, HAN J, RALPH W M, et al. Endoplasmic reticulum stress as a correlate of cytotoxicity in human tumor cells exposed to diindolylmethane in vitro. Cell Stress Chaperones, 2004, 9(1): 76-87.
HISS D C, GABRIELS G A, FOLB P I. Combination of tunicamycin with anticancer drugs synergistically enhances their toxicity in multidrug-resistant human ovarian cystadenocarcinoma cells . Cancer Cell Int, 2007, 7(5): 1-14.
HUONG P T, MOON D O, KIM S O, et al. Proteasome inhibitor-I enhances tunicamycin-induced chemosensitization of prostate cancer cells through regulation of NF-κB and CHOP expression . Cell Signal, 2011, 23(5): 857-865.
LELEU X, XU L, JIA X, et al. Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia . Blood, 2009, 113(3):626-634.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
基金
基金项目:国家重点基础研究发展计划(973计划)项目(2004CB518706)
{{custom_fund}}
PDF(1213 KB)
